Pioneering NAD+ Pharmaceuticals to Change the Way We Live and Age
Our Mission
To enable longer, healthier lives.
Metro International Biotech is a privately-owned clinical-stage pharmaceutical company advancing a leading portfolio of proprietary NAD+ precursors.
As NAD+ levels decline with age, restoring them offers broad therapeutic potential for health and metabolism. Backed by top scientists, Metro is developing MIB-626 and next-generation NAD+ analogs to drive innovation in aging and cellular health.
Leading the Way in Advancing NAD+ Science
World-Class Scientific Leadership
Scientific advisory board includes leading founders of the aging field, including experts such as Rajendra Apte, M.D., Ph.D., Johan Auwerx, M.D., Ph.D., James Ellis, Ph.D., Nick Lane, Ph.D., Jeffrey Lieberman, M.D., David Sinclair, A.O., Ph.D., Li-Huei Tsai, Ph.D., Lindsay Wu, Ph.D.
Exceptional Clinical Track Record
No drug-related SAEs observed across multiple clinical trials to date.
Rigorous Chemistry-Driven Strategy
Deep expertise in pharmacokinetics, pharmacodynamics, and early, preventive intervention strategies.
Proprietary NAD+ Imaging Technology
Access to in vivo MRS (magnetic resonance spectroscopy) with a 7-tesla magnet; this instrumentation is capable of measuring NAD+ directly in brain tissue.
Healthspan-Focused Development
Targeting not only disease treatment but also the improvement of functional health through enhanced muscular, renal, and cognitive function.
About Us
MetroBiotech is a clinical-stage biotechnology company developing first-in-class therapeutics that target NAD+ biology to enhance human healthspan and treat age-related diseases. Our mission is to address the root causes of aging-related conditions, improving quality of life and treating the diseases of aging.
What We’re Doing
NAD+ is critically important to the function of all living cells.
NAD+ levels have been shown to decline as humans age and research and preclinical models have demonstrated the broad therapeutic potential of increasing NAD+ to preserve health and normal metabolism.
MetroBiotech’s platform focuses on restoring and sustaining NAD+ levels, a critical cofactor for mitochondrial function, gene regulation, and cellular resilience. [Our early human trials demonstrated up to 200% increase in NAD+ levels within 14 days, without any drug-related serious adverse events (SAEs).]
Unlike over-the-counter supplements – often manufactured with inconsistent quality and impurity profiles – our compounds are produced under FDA oversight, adhering to pharmaceutical-grade manufacturing standards to ensure purity, safety, and bioavailability.
-
01 Eyes
Drooping eyelids, inability to move eyes, blindness, cataracts
-
02 Heart
Cardiomyopathy, conduction block
-
03 Liver
Liver failure (in mtDNA depletion syndrome), fatty liver
-
04 Kidneys
Fanconi’s syndrome, nephrotic syndrome (in coenzyme Q10 deficiency)
-
05 Nervous System
Seizures, spasms, developmental delays, deafness, dementia, stroke, visual defects, poor balance, peripheral neuropathy
-
06 Skeletal Muscle
Muscle weakness, exercise intolerance, cramps, myoglobinuria
-
07 Pancreas
Diabetes
-
08 Digestive Tract
Difficulty swallowing, vomiting, feeling of being full, chronic diarrhea, intestinal obstruction
Our Lead Programs
We are currently advancing a pipeline of novel NAD-boosting compounds:
MIB-626
Our lead drug candidate, MIB-626, is a novel, patented crystalline NAD+ booster with scalable manufacturing capabilities. It is currently in three Phase 2 clinical trials for Alzheimer’s disease, chronic kidney disease, and muscle strength and endurance.
MIB-725
A next-generation NAD+ precursor that will be under investigation for acute kidney injury (AKI) following cardiac surgery. Phase 1 safety and bioavailability studies commenced in Q1 2025.